0001179110-19-002313.txt : 20190222
0001179110-19-002313.hdr.sgml : 20190222
20190222161126
ACCESSION NUMBER: 0001179110-19-002313
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190220
FILED AS OF DATE: 20190222
DATE AS OF CHANGE: 20190222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Myer Vickesh
CENTRAL INDEX KEY: 0001742806
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37687
FILM NUMBER: 19625808
MAIL ADDRESS:
STREET 1: C/O EDITAS MEDICINE, INC.
STREET 2: 11 HURLEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Editas Medicine, Inc.
CENTRAL INDEX KEY: 0001650664
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464097528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11 HURLEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-401-9000
MAIL ADDRESS:
STREET 1: 11 HURLEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
edgar.xml
FORM 4 -
X0306
4
2019-02-20
0
0001650664
Editas Medicine, Inc.
EDIT
0001742806
Myer Vickesh
C/O EDITAS MEDICINE, INC.
11 HURLEY ST.
CAMBRIDGE
MA
02141
0
1
0
0
Chief Technology Officer
Common Stock
2019-02-20
4
M
0
3000
0.65
A
3000
D
Common Stock
2019-02-20
4
S
0
3000
20.42
D
0
D
Stock Option (right to buy)
0.65
2019-02-20
4
M
0
3000
0
D
2025-04-29
Common Stock
3000
76307
D
The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
This transaction was executed in multiple trades at prices ranging from $20.31 to $20.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.
/s/ Anthony Joyce, attorney-in-fact
2019-02-22